White Knight for Allos? SEC Docs Show Bidder Rejected
By Trista Morrison
Tuesday, September 20, 2011
The proposed merger of AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. has raised eyebrows from the start, but both firms remain committed to closing the deal, allowing neither criticism nor competing offers to stand in their way.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.